Group 1 - The core viewpoint of the article highlights that ST Nuotai (688076.SH) reported its 2025 annual performance, showing a revenue increase but a decline in net profit [1] - The company achieved an operating income of 1.94 billion yuan, representing a year-on-year growth of 19.57% [1] - The net profit attributable to the parent company was 327 million yuan, which reflects a year-on-year decrease of 19.14% [1] Group 2 - The overall sales revenue of the company increased during the reporting period [1] - The decline in gross profit margin was attributed to industry price fluctuations and an increase in fixed costs [1]

格隆汇2月27日丨ST诺泰(688076.SH)公布，近日收到国家药品监督管理局核准签发的依帕司他片的《药 品注册证书》，依帕司他片适应症为糖尿病性神经病变。依帕司他是一种可逆性的醛糖还原酶非竞争性 抑制剂，对醛糖还原酶具有选择性抑制作用。依帕司他片通过抑制糖尿病性外周神经病变患者红细胞中 山梨醇的积蓄，达到改善患者的自觉症状和神经功能障碍的效果。 ...

（记者 王晓波） 每经AI快讯，ST诺泰2月27日晚间发布公告称，江苏诺泰澳赛诺生物制药股份有限公司于近日收到国家 药品监督管理局核准签发的依帕司他片的《药品注册证书》。 每经头条（nbdtoutiao）——中美大反转，中国AI调用量首超美国，A股嗨了，多板块掀涨停潮！华尔 街知名分析师：中国算力路径颠覆传统认知 ...

证券代码：688076 证券简称：ST 诺泰 公告编号：2026-011 （一）资产减值损失 公司对固定资产、无形资产等长期资产，在资产负债表日有迹象表明发生减 江苏诺泰澳赛诺生物制药股份有限公司 关于 2025 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《企业会计准则》以及江苏诺泰澳赛诺生物制药股份有限公司（以下简 称"公司"）的会计政策、会计估计的相关规定，为了真实、准确地反映公司截 至2025年12月31日的财务状况和2025年度的经营成果，本着谨慎性原则，公司对 截至2025年12月31日公司及子公司的资产进行了减值测试，对存在减值迹象的资 产相应计提了减值准备，现将有关事项公告如下： 一、计提资产减值准备情况概述 2025年，公司计提资产减值准备总额为-9,189.23万元（损失以"-"号填列）。 具体情况如下表所示： 单位：万元 | 序号 | 项目 | 2025年计提金额 | 备注 | | --- | --- | --- | --- | | 1 | 信用减值损失（损失以 | - ...

证券代码：688076 证券简称：ST 诺泰 公告编号：2026-010 江苏诺泰澳赛诺生物制药股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司 2025 年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 1,942,799,144.82 | 1,624,801,884.87 | 19.57 | | 营业利润 | 400,048,003.86 | 448,218,444.01 | -10.75 | | 利润总额 | 351,899,817.71 | 438,504,152.57 | -19.75 | | 归属于母公司所有者 | 326,999,932.94 | 404,389,990.70 | -19.14 | ...

江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露依帕司他片获得药品注册证书的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生物"） 于近日收到国家药品监督管理局核准签发的依帕司他片的《药品注册证书》（证 书编号：2026S00470），现将相关情况公告如下： 一、《药品注册证书》的主要内容 药品名称：依帕司他片 证券代码：688076 证券简称：ST 诺泰 公告编号：2026-009 生产企业：江苏诺泰澳赛诺生物制药股份有限公司 药品批准文号：国药准字 H20263399 药品批准文号有效期：至 2031 年 02 月 09 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 剂型：片剂 规格：50mg 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 药品有效期：18 个月 包装规格：10 片/板，1 板/盒 上市许可持有人：江苏诺泰澳赛诺生物制药股份有限 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1 - The core issue involves investor claims against Nuotai Bio (688076) due to false statements leading to ongoing legal proceedings [1][5] - The Shanghai Financial Court has accepted the case for investor claims against Nuotai Bio, with further claims being processed [1][5] - Nuotai Bio's 2021 annual report was found to contain false records, including a reported revenue of 30 million yuan from a technology transfer that lacked commercial substance, inflating total revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported profit [1][5] Group 2 - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or held shares after October 24, 2024, are eligible to file claims [2][6] - The law firm is also handling claims for Century Huatong (002602), with a recent filing submitted to the Shaoxing Intermediate People's Court [2][6] - Century Huatong was found to have false records in its annual reports from 2018 to 2022, including fabricated software copyright transfer transactions and premature revenue recognition [3][7] Group 3 - Investors who bought Century Huatong shares between April 27, 2019, and July 25, 2023, and sold or held shares after July 25, 2023, can initiate claims [4][8] - The law firm has a history of successfully representing investors in similar cases, with many having received compensation [4][8]

Group 1: Gold and Silver Market Outlook - A Reuters survey indicates that gold prices are expected to reach a new high of $4,746.50 per ounce by 2026, driven by geopolitical uncertainties and strong central bank purchases, marking a significant increase from last year's forecast of $4,275 [1] - The average price expectation for silver in 2026 has also been raised to $79.50 per ounce, up from $50 in the previous year's survey [1] Group 2: Currency and Economic Analysis - The strong US dollar is exerting downward pressure on gold and silver prices, with analysts suggesting that if the dollar's rebound continues, it may further impact gold prices negatively [2] - UBS forecasts a 10% increase in global stock markets by the end of the year, with a focus on diversification into markets like China, Japan, and Europe, driven by strategic autonomy and fiscal expansion [3] - Mitsubishi UFJ reports that the Japanese yen has fallen to a near two-week low due to election expectations, with potential for continued selling pressure as confidence in the ruling party's stability grows [4] - Goldman Sachs warns of upward fiscal risks in Japan ahead of the upcoming elections, suggesting that unless the Bank of Japan accelerates interest rate hikes, the yen may weaken further [6] Group 3: Sector-Specific Insights - Zhongtai Securities expresses a positive outlook on the raw material pharmaceutical sector, highlighting innovations in small nucleic acids and ADC toxins as catalysts for growth [7] - CITIC Securities recommends focusing on automotive companies with strong cost transfer capabilities and global layouts, as rising raw material prices are expected to pressure profit margins in the first quarter of 2026 [8] - Galaxy Securities identifies two main paths for AI-driven benefits: enhancing platform efficiency and improving production efficiency through content and tools, suggesting a focus on internet stocks and AI-related applications [9]

公司始终坚持"时间领先、技术领先"的经营理念。本次建德工厂原料药生产线通过GMP符合性检查， 再次印证公司具备领先的生产及质量管理体系，对建德工厂创新药CDMO业务从高级中间体向原料药价 值延伸具有里程碑意义，对公司持续开拓创新药原料药客户具有积极意义。 ST诺泰(688076.SH)发布公告，公司全资子公司杭州澳赛诺生物科技有限公司(简称"澳赛诺"或"建德工 厂")于近日收到浙江省药品监督管理局签发的《药品GMP符合性检查告知书》(编号：浙2026第0013 号)，澳赛诺奥格特韦钠原料药正式通过GMP符合性检查。 ...